Richard C. Young & CO. LTD. Increases Position in Kenvue Inc. (NYSE:KVUE)

Richard C. Young & CO. LTD. lifted its holdings in Kenvue Inc. (NYSE:KVUE - Free Report) by 31.2% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 513,289 shares of the company's stock after buying an additional 121,976 shares during the period. Richard C. Young & CO. LTD.'s holdings in Kenvue were worth $12,309,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Fulton Bank N.A. boosted its stake in shares of Kenvue by 0.6% in the first quarter. Fulton Bank N.A. now owns 78,888 shares of the company's stock valued at $1,892,000 after purchasing an additional 465 shares during the period. Scott & Selber Inc. boosted its holdings in shares of Kenvue by 0.4% in the 1st quarter. Scott & Selber Inc. now owns 106,621 shares of the company's stock valued at $2,557,000 after buying an additional 475 shares in the last quarter. Keystone Financial Group boosted its holdings in shares of Kenvue by 4.8% in the 4th quarter. Keystone Financial Group now owns 12,736 shares of the company's stock valued at $272,000 after buying an additional 578 shares in the last quarter. Transatlantique Private Wealth LLC boosted its holdings in shares of Kenvue by 5.7% in the 4th quarter. Transatlantique Private Wealth LLC now owns 10,680 shares of the company's stock valued at $228,000 after buying an additional 580 shares in the last quarter. Finally, Byrne Asset Management LLC boosted its holdings in shares of Kenvue by 1.0% in the 1st quarter. Byrne Asset Management LLC now owns 63,467 shares of the company's stock valued at $1,522,000 after buying an additional 621 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Kenvue Stock Performance

Kenvue stock traded up $0.15 during trading hours on Friday, reaching $22.00. 12,727,162 shares of the stock were exchanged, compared to its average volume of 16,300,086. The stock has a market cap of $42.21 billion, a P/E ratio of 40.00, a P/E/G ratio of 3.40 and a beta of 0.83. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.60 and a current ratio of 0.86. Kenvue Inc. has a 52-week low of $17.85 and a 52-week high of $25.17. The firm's 50 day moving average is $22.20 and its 200 day moving average is $22.30.

Kenvue (NYSE:KVUE - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported $0.24 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.23 by $0.01. The business had revenue of $3.74 billion during the quarter, compared to the consensus estimate of $3.69 billion. Kenvue had a net margin of 6.90% and a return on equity of 20.87%. The business's revenue was down 3.9% compared to the same quarter last year. During the same quarter last year, the firm posted $0.28 EPS. Analysts predict that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on KVUE shares. Bank of America lowered their target price on shares of Kenvue from $27.00 to $25.00 and set a "buy" rating for the company in a report on Tuesday. Barclays dropped their price objective on shares of Kenvue from $23.00 to $22.00 and set an "equal weight" rating on the stock in a research note on Tuesday. Redburn Atlantic began coverage on shares of Kenvue in a research note on Thursday, April 10th. They issued a "neutral" rating and a $23.50 price objective on the stock. Evercore ISI began coverage on shares of Kenvue in a research note on Monday, March 24th. They issued an "in-line" rating and a $25.00 price objective on the stock. Finally, UBS Group dropped their price objective on shares of Kenvue from $25.00 to $23.00 and set a "neutral" rating on the stock in a research note on Thursday. Seven investment analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $24.71.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.